Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Selexis SA and Turgut Pharmaceuticals Expand Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Selexis SA and Turgut Pharmaceuticals Expand Agreement

The expanded partnership adds onto the two existing commercial license agreements between the companies

By: Betsy Louda

, Contract Pharma

Selexis SA and Turgut Pharmaceuticals have entered into a third commercial license agreement that provides Turgut with access to Selexis’ SUREtechnology Platform and SURE CHO-M Cell Line for the development of a high-quality biosimilar product for the treatment of two ultra-rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The new agreement builds on two commercial license agreements established between the companies in July 2016 to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.

 

Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including biosimilars, and provides seamless integration of the biologics development continuum, spanning discovery to commercialization. The SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. 

 

“At Selexis, we value our role in contributing to the success of partners like Turgut Pharmaceuticals who are working to bring additional therapeutic options to patients who are facing complex, and sometimes life-threatening, diseases,” said Marco Bocci, PhD, DPharm, Selexis vice president of licensing and business development. 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics